The analysis, which was released on the first day of the meeting, was one of many that tried to demonstrate that earlier treatment in newly diagnosed and younger patients may forestall disease progression and disability.
Ofatumumab, a targeted B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS), significantly reduced the relapse rate in a subgroup of patients who were treatment naïve and had a new diagnosis, according to study results presented Friday at the MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting.
The post hoc data were announced by Novartis, which markets the drug under the name Kesimpta. The FDA approved the drug last month; it is administered by patients once a month through the Sensoready autoinjector pen. Ofatumumab was first approved by the FDA in 2009 for the treatment of chronic lymphocytic leukemia as an intravenous infusion.
The analysis, which was released on the first day of the meeting, was one of many that tried to demonstrate that earlier treatment in younger patients with a new diagnosis may forestall disease progression and disability.
The phase 3 ASCLEPIOS I and II trials (n = 615) evaluated the efficacy and safety profile of treatment with ofatumumab in a subgroup of patients with early RMS (newly diagnosed and treatment naïve). The median age and duration of their MS since diagnosis were 36 and 0.35 years, respectively.
Compared with teriflunomide, results showed that ofatumumab:
Overall, ofatumumab had a similar safety profile to teriflunomide, the company said in a statement.
Adverse events (AEs) occurred in 84.7% ofatumumab- vs 86.0% teriflunomide-treated patients; serious AEs (SAEs) were reported in 7.0% and 5.3%, respectively. Infection rates were comparable between ofatumumab (56.1%) and teriflunomide (56.5%); serious infections rates were 1.9% and 0.7%, respectively, and no opportunistic infections were reported.
"These encouraging data show that newly diagnosed and treatment-naïve patients may benefit from lower disease activity when treated with Kesimpta," said Amit Bar-Or, MD, FRCP, FAAN, FANA, the inaugural Melissa and Paul Anderson President’s Distinguished Professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania, director of the Center for Neuroinflammation and Experimental Therapeutics, and chief of the Division of Multiple Sclerosis and Related Disorders.
An additional post hoc analysis of the same subgroup showed that the odds of achieving no evidence of disease activity (NEDA-3; no relapses, no MRI lesions, and no disability worsening combined) with ofatumumab vs teriflunomide were more than 3-fold higher at the first year (47.0% vs 24.7% of patients; P <.001) and more than 14-fold higher at the second year of treatment (92.1% vs 46.8% of patients; P <.001).
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More